Fulcrum Therapeutics Inc (FULC) 13F Investor Activity Report (Q2 2026)

FULC ranks #3601 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

155 institutions disclose a position in FULC, but none treat it as a major bet — even EcoR1 Capital, LLC, its most concentrated holder, allocates just 1.2% of its own portfolio to it.

Israel Englander has added to its FULC position for two straight quarters, increasing it by $4.8M to reach $5.4M today.

Montanova Capital, LLC has trimmed its FULC position for two straight quarters, cutting it by $60.7M while still holding $13.5M.

FULC is down 0% today, but institutions show net buying of $128.8M this quarter — a divergence between today's price move and the underlying institutional flow.

FULC reported a net loss of $74.9M in its latest fiscal year.

• Not yet profitable — net loss of $74.9M in the latest fiscal year
• Revenue declined 100.0% year over year
• Net income declined year over year, from -$9.7M to -$74.9M
• Operating cash flow was negative, using $60.1M in cash
• Current ratio of 27.40x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.05x equity — within a conventional range